All times are listed in CEST (Central European Summer Time)
- Domenica Lorusso (Rome, Italy)
- Sven Mahner (München, Germany)
LBA40 - Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma
- Nicoletta Colombo (Milan, Italy)
Abstract
Background
The standard therapy for advanced/recurrent endometrial cancer includes carboplatin and paclitaxel (CP). Robust biological rationale suggested a synergy between immunotherapy and chemotherapy in this setting.
Methods
AtTEnd is an international academic study in endometrial carcinoma/carcinosarcoma patients (pts) with advanced newly diagnosed or recurrent disease with no prior systemic chemotherapy for recurrence. Pts were randomized (2:1 ratio) to receive either CP chemotherapy and atezolizumab (atezo) or placebo, followed by atezo or placebo until disease progression. The mismatch repair (MMR) status was evaluated centrally. Coprimary endpoints with a hierarchical approach were: progression free survival (PFS) in the deficient MMR (dMMR) population, PFS and overall survival (OS) in all comers.
Results
Five hundred and fifty-one pts were enrolled from Oct 2018 to Jan 2022 in 89 sites across 10 countries (median follow-up 28.3 months). Of the 549 pts included in the intention to treat population, 125 (22.8%) had dMMR tumours and 352 (64.1%) had endometrioid carcinoma; 369 (67.2%) had recurrent disease and 148 (82.2%) of newly diagnosed cases had primary stage IV. In the dMMR population, the addition of atezo showed a significant improved PFS (HR 0.36 95% CI:0.23-0.57; p=0.0005; median PFS: not reached vs. 6.9 months for atezo vs placebo). The superiority in PFS was confirmed in all comers (HR 0.74 95%CI:0.61-0.91; p=0.0219; median PFS: 10.1 months vs 8.9 months for atezo vs placebo). Interim analysis of OS in all comers indicated a trend in favor for atezo, despite 45 (24.3%) placebo patients received immunotherapy as subsequent therapy. Second PFS and duration of response in the dMMR population confirmed the efficacy of atezo. Grade≥3 adverse events occurred in 66.9% and 63.8% of pts in atezo vs placebo arm. Safety profile for CP + atezo was manageable and consistent with expected toxicities.
Conclusions
The addition of atezo to standard CP chemotherapy demonstrated a statistically significant improvement in PFS for pts with advanced/recurrent endometrial carcinomas with a substantial benefit in pts with dMMR carcinomas.
Clinical trial identification
EudraCT 2018-001072-37; NCT03603184.
Legal entity responsible for the study
Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Funding
F. Hoffmann-La Roche Ltd.
Disclosure
N. Colombo: Financial Interests, Personal, Advisory Board, Various: Roche, PharmaMar, AstraZeneca, MSD/Merck, Clovis Oncology, GSK, Pfizer, Immunogen, Mersana; Financial Interests, Personal, Invited Speaker, Congress, Symposia, Lectures: AstraZeneca; Financial Interests, Personal, Invited Speaker, Lectures: Novartis; Financial Interests, Personal, Advisory Board, Lectures: Eisai; Financial Interests, Personal, Advisory Board, Advisory role: Nuvation Bio, Pieris; Financial Interests, Personal, Advisory Board, Advisory Role: Onxerna; Financial Interests, Institutional, Research Grant: AstraZeneca, PharmaMar, Roche; Non-Financial Interests, Other, Sterring committee member Clinical Guidelines: ESMO; Non-Financial Interests, Leadership Role, Chair, Scientific Committee: ACTO( Alleanza contro il tumore ovarico). K. Harano: Financial Interests, Personal, Invited Speaker: AstraZeneca, MSD, Takeda; Financial Interests, Personal, Advisory Board: Daiichi Sankyo, Chugai, Takeda; Financial Interests, Institutional, Research Grant: Merck, Daiichi Sankyo; Financial Interests, Institutional, Local PI: MSD, Daiichi Sankyo, Takeda; Non-Financial Interests, Principal Investigator: Merck, Chugai. Y. Antill: Financial Interests, Personal, Advisory Board: GSK, Eisai, MSD; Financial Interests, Personal, Advisory Board, Coordinating PI: AstraZeneca. F. Marmé: Financial Interests, Personal, Invited Speaker: AstraZeneca, GSK/Tesaro, Clovis, Pfizer, Lilly; Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Novartis, Roche, Gilead/immunomedics, EISAI, PharmaMar, GenomicHealth, Myriad, Seagen; Financial Interests, Institutional, Invited Speaker: Seagen, Daiichi Sankyo, GSK, AstraZeneca; Financial Interests, Institutional, Advisory Board: Roche, Immunicom; Financial Interests, Institutional, Local PI: Roche, Novartis, Eisai, MSD, Vaccibody, GSK; Financial Interests, Institutional, Coordinating PI: AstraZeneca, Roche, Gilead/Immunomedics, German Breast Group, AGO Research GmbH; Financial Interests, Institutional, Funding: AstraZeneca, Lilly, Seagen. E. Petru: Financial Interests, Personal, Advisory Board, Attendance fees: AstraZeneca, EISAI, Lilly, GSK; Financial Interests, Personal, Invited Speaker, Lecture fees: AstraZeneca, EISAI, Lilly, GSK; Financial Interests, Personal, Advisory Board, Fees: MSD, Novartis, Pharma Mar, Roche, Seagen, Pierre fabre, Daiichi Sankyo, GILEAD; Financial Interests, Personal, Invited Speaker, Fees: MSD, Novartis, Roche, Daiichi Sankyo; Financial Interests, Personal, Invited Speaker: Seagen; Financial Interests, Personal, Local PI, Fees to institution: AstraZeneca; Financial Interests, Institutional, Local PI, Patient Fees: Roche; Financial Interests, Institutional, Local PI, Fees: Daiichi Sankyo, Lilly, GSK, Novartis; Financial Interests, Institutional, Local PI, FEES: Seagen, Pierre Fabre. C. Lai: Non-Financial Interests, Personal, Coordinating PI, President: TGOG; Financial Interests, Personal, Full or part-time Employment: CGMH; Non-Financial Interests, Personal, Affiliate, Past President: TGOG. L. Fariñas Madrid: Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Institutional, Invited Speaker: AstraZeneca&MSD; Financial Interests, Personal, Invited Speaker: EISAI, GSK. Y.C. Lee: Financial Interests, Institutional, Invited Speaker, Educational events: AstraZeneca; Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Institutional, Research Grant: BeiGene. C. Zamagni: Financial Interests, Personal, Advisory Board: Roche, EISAI, Novartis, AstraZeneca, Pfizer, Lilly, Daiichi Sankyo, Exact Sciences, MSD, GSK, Gilead, Seagen; Financial Interests, Institutional, Local PI: Roche, Novartis, AstraZeneca, Pfizer, Seagen, Medivation, AbbVie, Array BioPharma, Morphotek, Synthon, Daiichi-Sankyo, MSD, GSK, Gilead; Financial Interests, Personal, Other, Member of an Independent Data Monitoring Committee for an international clinical trial: AstraZeneca; Non-Financial Interests, Other, member of the Scientific Committee: LOTO Onlus, Susan J Komen Emilia-Romagna, Mamazone Sudtirol; Other, travel accomodation and partecipation expenses for scientific congresses: Roche, Novartis, Pfizer, Daiichi Sankyo, MSD, GSK, Gilead, AstraZeneca. G. Tasca: Financial Interests, Advisory Board: GSK, AstraZeneca, MSD; Financial Interests, Steering Committee Member: GSK; Financial Interests, Speaker’s Bureau: GSK, AstraZeneca; Financial Interests, Other, Travel Expenses: PharmaMar. M.P. Barretina Ginesta: Financial Interests, Personal, Advisory Board: AstraZeneca, GSK, MSD, EISAI, PharmaMar; Financial Interests, Personal, Invited Speaker: AstraZeneca, GSK, MSD; Financial Interests, Personal, Steering Committee Member: MSD. All other authors have declared no conflicts of interest.
Invited Discussant LBA40
- David SP Tan (Singapore, Singapore)
Q&A
- All Speakers (Lugano, Switzerland)
LBA41 - Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first-line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): Results from the phase III DUO-E/GOG-3041/ENGOT-EN10 trial
- Shannon N. Westin (Houston, United States of America)
Abstract
Background
Combination of immunotherapy with CP led to improved progression-free survival (PFS) in patients (pts) with advanced EC. DUO-E (NCT04269200) evaluated addition of durva to standard 1L CP, followed by mtx durva ± ola, in pts with EC.
Methods
Pts with newly diagnosed FIGO Stage III/IV or recurrent EC and naïve to systemic treatment were randomised 1:1:1 to CP (CP + durva placebo [pbo] for 6 cycles followed by mtx durva pbo + ola pbo), CP + durva (CP + durva [1120 mg IV q3w] for 6 cycles followed by mtx durva [1500 mg IV q4w] + ola pbo), or CP + durva + ola (CP + durva for 6 cycles followed by mtx durva + ola [300 mg tablets bid]). Dual primary endpoints were PFS (investigator-assessed RECIST v1.1) in the intent-to-treat (ITT) population for CP + durva vs CP and CP + durva + ola vs CP; overall survival (OS) was a secondary endpoint. A multiple testing procedure with gatekeeping strategy was applied to PFS and OS. PFS by mismatch repair (MMR) status was a prespecified subgroup analysis.
Results
In the ITT population (N=718), CP + durva and CP + durva + ola showed statistically significant and clinically meaningful PFS benefit vs CP (Table). Interim OS data were immature (27.7%) yet with a trend towards benefit (CP + durva vs CP: HR [95% CI] 0.77 [0.56–1.07];
| Population | Arm | Median follow-up duration,† months | PFS events, n/N (%) | Median PFS, months | HR* (95% CI) | 12-/18-month PFS rate, % |
| ITT | CP | 12.6 | 173/241 (71.8) | 9.6 | 41.1/21.7 | |
| CP + durva | 15.4 | 139/238 (58.4) | 10.2 | 0.71 (0.57–0.89); | 48.5/37.8 | |
| CP + durva + ola | 15.4 | 126/239 (52.7) | 15.1 | 0.55 (0.43–0.69); | 61.5/46.3 | |
| dMMR | CP | 10.2 | 25/49 (51.0) | 7.0 | 43.3/31.7 | |
| CP + durva | 15.5 | 15/46 (32.6) | Not reached | 0.42 (0.22–0.80) | 67.9/67.9 | |
| CP + durva + ola | 19.2 | 18/48 (37.5) | 31.8 | 0.41 (0.21–0.75) | 70.0/62.7 | |
| pMMR | CP | 12.8 | 148/192 (77.1) | 9.7 | 40.8/20.0 | |
| CP + durva | 15.3 | 124/192 (64.6) | 9.9 | 0.77 (0.60–0.97) | 44.4/31.3 | |
| CP + durva + ola | 15.2 | 108/191 (56.5) | 15.0 | 0.57 (0.44–0.73) | 59.4/42.0 |
*Vs CP; †In censored patients.
Conclusions
DUO-E met both primary endpoints, showing statistically significant and clinically meaningful PFS improvement with the addition of durva to CP followed by maintenance durva ± ola vs CP alone. Mtx ola further improved PFS in pts with pMMR disease.
Clinical trial identification
D9311C00001; NCT04269200.
Editorial acknowledgement
Medical writing assistance was provided by Simone Boldt, PhD, at Cence, funded by AstraZeneca.
Legal entity responsible for the study
AstraZeneca.
Funding
This study was funded by AstraZeneca.
Disclosure
S.N. Westin: Financial Interests, Institutional, Research Grant: AstraZeneca, AvengeBio, Bayer, Bio-Path, Clovis Oncology, GSK, Mereo, Novartis, Roche/Genentech, Zentalis; Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Caris, Clovis Oncology, Eisai, EQRX, Gilead, GSK, ImmunoGen, Lilly, Merck, Mereo, Mersana, NGM Bio, Nuvectis, Roche/Genentech, SeaGen, Verastem, Vincerx, Zentalis, ZielBio. K.N. Moore: Financial Interests, Personal, Advisory Board: AstraZeneca, Aravive, Alkemeres, Blueprint Pharma, Eisai, Emd Serono, GSK/Tesaro, Genentech/Roche, Hengrui, Immunogen, IMab, Mereo, Myriad, Caris, Mersana, Novartis, Novocure, OncXerna, OncoNova, Tarveda, VBL Therapeutics, Clovis, Caris, Lilly, Nonvartis, Pannavance, Verastem, Zentalis, Merck; Financial Interests, Institutional, Advisory Board, advisory board work for gynecologic trial: Aadi; Financial Interests, Institutional, Advisory Board, work on clinical trial and planning for next trial: duality; Financial Interests, Personal, Full or part-time Employment: GOG Partners Associate Director; Financial Interests, Institutional, Full or part-time Employment: NRG Ovarian Cancer Chair; Financial Interests, Personal, Member of Board of Directors, not reimbursed: ASCO; Financial Interests, Institutional, Member of Board of Directors, not reimbursed: GOG Foundation; Financial Interests, Personal, Royalties: UP to Date; Financial Interests, Institutional, Coordinating PI, international CO-PI, local site PI: AstraZeneca; Financial Interests, Institutional, Coordinating PI: Immunogen, GSK/Tesaro, PTC Therapeutics, duality; Financial Interests, Institutional, Local PI: Lilly, Daiichi Sankyo, Regeneron, Artios, Bolt, verastem; Non-Financial Interests, Member of Board of Directors: GOG. J. Lee: Financial Interests, Personal, Invited Speaker: AstraZeneca, Takeda, MSD, Roche; Financial Interests, Personal, Advisory Board: Eisai, GI Innovation; Financial Interests, Institutional, Local PI: Alkermes, AstraZeneca, BergenBio, Cellid, Clovis Oncology, Eisai, GI Innovation, ImmunoGen, Janssen, Merck, Mersana, MSD, Novartis, OncoQuest, Roche, Seagen, Synthon; Financial Interests, Personal and Institutional, Local PI: BeiGene; Financial Interests, Personal, Steering Committee Member: AstraZeneca, OncoQuest, Seagen, ImmunoGen, MSD; Financial Interests, Institutional, Research Grant: ONO, Takeda. M. Sundborg: Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Personal, Speaker, Consultant, Advisor: GSK. J. de la Garza: Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Merck, Seagen; Non-Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Other, DaVinci Robot proctor: Intuitive. T. Tillmanns: Financial Interests, Personal, Speaker, Consultant, Advisor: GSK, Eisai. F. Contreras Mejia: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, Eli-Lilly, GSK, MSD, Novartis; Financial Interests, Personal, Advisory Board: BMS, Eli-Lilly, Janssen; Financial Interests, Personal, Expert Testimony: GSK, MSD. A.C. de Melo: Financial Interests, Institutional, Research Grant: Amgen, AstraZeneca, Bristol Myers Squibb, Clovis Oncology, GSK, Merck Sharp & Dohme, Novartis, Regeneron, and Roche; Financial Interests, Personal, Other, Honoraria for lectures: AstraZeneca, Bristol Myers Squibb, GSK, Merck Sharp & Dohme, Novartis, Roche, and Sanofi; Financial Interests, Personal, Advisory Board: AstraZeneca, Bristol Myers Squibb, GSK, Merck Sharp & Dohme, Novartis, and Roche. D. Klasa-Mazurkiewicz: Financial Interests, Personal, Other, Honoraria for lectures: AstraZeneca, GSK and Roche. C.A. Papadimitriou: Financial Interests, Personal, Other, Honoraria: Novartis, AstraZeneca, Genesis, MSD Oncology, Servier, WinMedica; Financial Interests, Personal, Advisory Role: Amgen, Astellas, BioPharma, Roche Hellas, AstraZeneca; Financial Interests, Institutional, Research Funding: Roche Hellas, WinMedica, Servier. M. Gil Martín: Financial Interests, Personal, Invited Speaker: MSD, AstraZeneca, GSK; Financial Interests, Personal, Other, Registration and attending scientific meetings: MSD, Clovis, GSK.. B. Brasiuniene: Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Expert Testimony: AstraZeneca; Financial Interests, Personal, Other, Reimbursement of travel expenses: AstraZeneca; Non-Financial Interests, Personal, Advisory Board, Member of NSGO and NSGO-CTU scientific committee member: NSGO. C. Donnelly: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. X. Liu: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. E. Van Nieuwenhuysen: Financial Interests, Institutional, Advisory Board: Regeneron, Oncoinvent; Financial Interests, Institutional, Local PI: Regeneron, Oncoinvent, Roche, Seagen, Merck, Novartis; Financial Interests, Institutional, Steering Committee Member: AstraZeneca; Financial Interests, Institutional, Coordinating PI: AstraZeneca. All other authors have declared no conflicts of interest.
LBA42 - Olaparib vs placebo as maintenance therapy after platinum-based chemotherapy in advanced/metastatic endometrial cancer patients: The GINECO randomized phase IIb UTOLA trial
- Florence Joly Lobbedez (Caen, Cedex 5, France)
Abstract
Background
The TGCA data suggest opportunities to target DNA repair in patients (pts) with endometrial cancer (EC). UTOLA assessed the efficacy of Parp-inhibitor maintenance for advanced/M+ EC pts who achieved disease control after 1st line platinum CT and to analyse efficacy in some molecular subgroups.
Methods
UTOLA is a randomized, double-blind, placebo controlled, phase IIb trial. Adjuvant CT ≥12 mos before inclusion was allowed. Pts were randomized (2:1) to olaparib maintenance arm (ola, 300 mg po BID) or placebo arm (pl) until progression or intolerance with stratification on P53, MMR status, and the response to the previous CT. Molecular profile was assessed by IHC and NGS. Primary endpoint was PFS in ITT. Main secondary endpoints were PFS according to P53 status, CT response, OS, safety. A pre-specified PFS analysis was performed according to HRD status defined by the number of large genomic events. One sided unstratified analyses are presented.
Results
147 pts were randomized (98 to Ola, 49 to pl). 82% of the pts received at least 6 cycles of CT with 46 CR, 64 PR, 34 stable and 3 NED; tumor classification was 53% P53mut, 35% NSMP, 12% MMRd, and 1 tumor POLEmut. In total, 52% (73) were HRD positive, 79% in P53mut & 23% in P53WT. Median PFS in the ITT population was 5.6 mos (90%CI 3.8-7.4) and 4.0 (3.6-7.4) in ola and pl arms respectively (HR:0.94, p=0.29). Median PFS in P53mut were 5.6 mos (3.6-8.8) vs 3.6 ms (1.8-4.9) in ola and pl arms (HR:0.75, p=0.12) whereas 6.1 mos (3.6-11) vs 7.7 mos (2.9-14.5) (HR=1.13, p=0.3) respectively in the P53WT. In the HRD tumors (n=73), median PFS was statistically higher with ola: 5.4 mos (90%CI 3.6-9.6) vs 3.6 mos (1.8-4.9) with pl (HR:0.59, p=0.02) regardless of P53 status. For the 46 pts with CR to previous CT, median PFS in ola arm reached 8.8 mos versus 3.8 mos. No difference for OS was observed in all subgroups. Safety profile was similar and acceptable as seen in other cancers (36% vs 10% of G3/4 toxicities without myelodysplasia with ola).
Conclusions
UTOLA suggests maintenance ola could prolong PFS in HRD-positive advanced/M+ EC. These data should be confirmed and warrants further PARP inhibitor studies in this population.
Clinical trial identification
EudraCT 017-002623-13.
Legal entity responsible for the study
ARCAGY-GINECO.
Funding
AstraZeneca.
Disclosure
F. Joly Lobbedez: Financial Interests, Personal, Advisory Board: GSK, AstraZeneca, MSD, Janssen, Ipsen, BMS, Bayer, Eisai; Financial Interests, Personal, Invited Speaker: GSK, AstraZeneca, MSD, Janssen, Ipsen, Amgen, Astellas; Financial Interests, Institutional, Coordinating PI: GSK, AstraZeneca; Financial Interests, Institutional, Research Grant: BMS; Other, travel: MSD, GSK. A. Leary: Financial Interests, Personal, Advisory Board: Zentalis; Financial Interests, Personal, Invited Speaker, Educational: GSK, Medscape; Financial Interests, Personal, Writing Engagement, Educational: Onko+; Financial Interests, Institutional, Other, Steering committee: MSD; Financial Interests, Institutional, Advisory Board: GSK, AstraZeneca, Clovis, Ability Pharma, MSD, Merck Serono, Apmonia, Blueprint; Financial Interests, Institutional, Invited Speaker, Educational: Kephren publishing; Financial Interests, Institutional, Other, Consultancy: Orion; Financial Interests, Institutional, Invited Speaker: AstraZeneca, Clovis; Financial Interests, Personal, Other, Consultancy: GLG; Financial Interests, Institutional, Research Grant, PI translational research: ARCAGY-GINECO, Sanofi, AstraZeneca; Financial Interests, Institutional, Funding, CI clinical trial: AstraZeneca; Financial Interests, Institutional, Research Grant, Int CI clinical trial: OSE immuno; Financial Interests, Institutional, Funding, PI clinical trial: Agenus, BMS, Iovance, GSK; Financial Interests, Institutional, Funding, PI 5 clinical trials: Roche; Financial Interests, Institutional, Funding, PI 2 clinical trials: AstraZeneca; Financial Interests, Institutional, Funding, PI 3 clinical trials and steering committee: MSD; Non-Financial Interests, Institutional, Other, Academic research project: Owkin, LXRepair; Non-Financial Interests, Personal, Proprietary Information, IDMC member: Clovis; Non-Financial Interests, Personal, Proprietary Information, IDMC chair: Pfizer; Non-Financial Interests, Member: GCIG. I.L. Ray-Coquard: Financial Interests, Personal, Advisory Board: Roche, GSK, AstraZeneca, Mersana, Deciphera, Amgen, Oxnea, Merck Sereno, Agenus, Novartis, Macrogenics, Clovis, EQRX, adaptimmun, Esai, SUTRO, BMS, Adaptimmune, Daiichi-Santyo; Financial Interests, Institutional, Other, COLIBRI translational research: BMS; Financial Interests, Institutional, Advisory Board, translational research NEOPREMBROV trial: MSD; Non-Financial Interests, Principal Investigator: PAOLA1; Non-Financial Interests, Other, President: GINECO. B. Asselain: Financial Interests, Advisory Board: DIALOG, Pierre Fabre; Financial Interests, Advisory Role: AstraZeneca, Daiichi Sankyo, Gilead; Financial Interests, Other, Training in Biostatistics: Servier, Roche. M.J. Rodrigues: Financial Interests, Personal, Invited Speaker: Immunocore; Financial Interests, Personal, Advisory Board: GSK, AstraZeneca; Financial Interests, Institutional, Coordinating PI: Johnson & Johnson; Non-Financial Interests, Institutional, Product Samples: MSD. L. Gladieff: Financial Interests, Personal, Other, Congress funding: VIATRIS, Roche; Financial Interests, Institutional, Invited Speaker: MSD, Clovis, GSK, Eisai; Financial Interests, Institutional, Advisory Board: CLOVIS, GSK; Financial Interests, Personal, Invited Speaker: AstraZeneca. F. Bazan: Financial Interests, Personal, Advisory Board: Daiichi Sankyo, Novartis, Eisai, Menarini; Financial Interests, Personal, Invited Speaker: Astra-Zeneca. C. Lebreton: Financial Interests, Personal, Advisory Board: GSK, GSK, MSD, Eisai, CLOVIS Oncology. L. Bengrine Lefevre: Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Personal, Invited Speaker: Servier, Eisai; Non-Financial Interests, Personal, Other: SOFOG, DIALOG. K. Leroy: Financial Interests, Personal, Other, scientific collaboration, speaker fees: Roche; Financial Interests, Personal, Invited Speaker: AstraZeneca, Janssen, Amgen, MSD, GSK; Non-Financial Interests, Principal Investigator, REALM study: Roche. R. Leman: Financial Interests, Institutional, Speaker, Consultant, Advisor, JEBP2023 - 2022-DIAG-0119: AstraZeneca; Financial Interests, Institutional, Speaker, Consultant, Advisor, AR_Staff_CFB-Biopathologie_23052023: AstraZeneca. P. Fournel: Financial Interests, Personal, Advisory Board: BMS, Sanofi, Janssen; Financial Interests, Personal, Invited Speaker: AstraZeneca, MSD, Amgen; Financial Interests, Personal, Other, Congress invitation: Takeda; Financial Interests, Institutional, Local PI: BMS, IPSEN. F. Selle: Financial Interests, Personal, Other: AstraZeneca, GSK Tesaro, MSD, Sandoz (Novartis), Clovis Oncology; Financial Interests, Institutional, Other: Roche, GSK-Tesaro, AstraZeneca, Immunogen, Incyte, Agenus. J. Frenel: Financial Interests, Personal, Advisory Board: Pfizer, Novocure, Pierre Fabre, Eisai, Seagen, Gilead; Financial Interests, Personal, Invited Speaker: GSK, Amgen; Financial Interests, Institutional, Advisory Board: Exactscience, Lilly, Daiichi Sankyo, AstraZeneca, Clovis Oncology; Financial Interests, Institutional, Invited Speaker: Novartis, MSD; Financial Interests, Coordinating PI: AstraZeneca, Seagen; Financial Interests, Local PI: MSD, Daiichi Sankyo; Non-Financial Interests, Principal Investigator: Novartis, Lilly, AstraZeneca, Pfizer, Daiichi Sankyo, MSD. Y. Fernandez: Financial Interests, Personal, Advisory Board: TESARO; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Institutional, Local PI: GSK, AstraZeneca, Pfizer; Non-Financial Interests, Personal, Member: ASCO, ESMO, ESGO. C. Foa: Financial Interests, Personal, Other, speaker / participation in a speaker’s bureau: Roche, MSD, AstraZeneca. B. You: Financial Interests, Personal, Advisory Role: MSD, Astra-Zeneca, GSK-Tesaro, Bayer, Roche-Genentech, ECS Progastrine, Novartis, LEK, Amgen, Clovis Oncology, Merck Serono, BMS, Seagen, Myriad, Menarini, Gilead, Eisai. J. Alexandre: Financial Interests, Personal, Advisory Board: Eisai, MSD, GSK, Janssen, Pfizer; Financial Interests, Personal, Invited Speaker: Eisai, MSD, AstraZeneca, GSK, Novartis; Financial Interests, Institutional, Research Grant: Janssen, GSK, MSD; Financial Interests, Institutional, Local PI: MSD, Eisai, Agenus, GSK, Immunogen, Incyte. All other authors have declared no conflicts of interest.
Invited Discussant LBA41 and LBA42
- Domenica Lorusso (Rome, Italy)
Q&A
- All Speakers (Lugano, Switzerland)